FibroGENE: A gene-based model for staging liver fibrosis.
Eslam, Mohammed; Hashem, Ahmed M; Romero-Gomez, Manuel; Berg, Thomas; Dore, Gregory J; Mangia, Alessandra; Chan, Henry Lik Yuen; Irving, William L; Sheridan, David; Abate, Maria Lorena; Adams, Leon A; Weltman, Martin; Bugianesi, Elisabetta; Spengler, Ulrich; Shaker, Olfat; Fischer, Janett; Mollison, Lindsay; Cheng, Wendy; Nattermann, Jacob; Riordan, Stephen; Miele, Luca; Kelaeng, Kebitsaone Simon; Ampuero, Javier; Ahlenstiel, Golo; McLeod, Duncan; Powell, Elizabeth; Liddle, Christopher; Douglas, Mark W; Booth, David R; George, Jacob.
; 64(2): 390-398, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26592354
Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
Paraoxonase activity in sera of patients with non-alcoholic fatty liver disease.
Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
[Progress in the Management of NAFLD/NASH].
PRO12ALA POLYMORPHISM ASSOCIATION OF PPAR-Î³ GENE WITH BIOCHEMICAL PARAMETERS OF THE BLOOD IN PATIENTS WITH CHRONIC DIFFUSE LIVER DISEASES.
Non-alcoholic Fatty Liver Disease (NAFLD)--A Review.
Preserved hemostatic status in patients with non-alcoholic fatty liver disease.
Reply to: "Procoagulant imbalance in patients with non-alcoholic fatty liver disease".
Nonalcoholic steatohepatitis in nonobese patients: Not so different after all.
Comments on "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis".